Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6720
-0.0180 (-2.61%)
Aug 18, 2026, 11:08 AM EDT - Market open
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $5.19K in the twelve months ending June 30, 2026, down -99.38% year-over-year. In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%.
Revenue (ttm)
$5.19K
Revenue Growth
-99.38%
P/S Ratio
1,675.58
Revenue / Employee
$648
Employees
8
Market Cap
8.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 285.76K | -1.22M | -80.98% |
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Xenetic Biosciences | 3.26M |
| Traws Pharma | 2.73M |
| Exicure | 500.00K |
| Lisata Therapeutics | 100.00K |
| Soligenix | 2.34K |
APRE News
- 1 day ago - Aprea Therapeutics reports Q2 EPS (7c), consensus (22c) - TheFly
- 6 days ago - Aprea Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire
- 6 days ago - Aprea Therapeutics Earnings release: Q2 2026 - Filings
- 6 days ago - Aprea Therapeutics Quarterly report: Q2 2026 - Filings
- 6 days ago - Aprea Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - GlobeNewsWire